| 摘要: |
| 目的：观察局部注射重组人干扰素α1b注射液治疗儿童寻常疣的疗效及副作用。方法：将116例确诊为寻常疣患儿随机分为治疗组和对照组各58例。治疗组常规消毒，抽取适量重组人干扰素α1b注射液，注入疣体基底部，直至疣体局部皮肤变白，间隔一周注射一次并观察其疗效；对照组采用CO2激光，用同样的方法消毒后，将激光机治疗头对准疣体烧灼，1个月复诊，半年后随访观察。结果：治疗组有效率为89.7%，对照组为91.0%，两组比较差异无统计学意义（P>0.05）。治疗组红肿3例，无水疱及感染；对照组红肿58例，水疱28例，感染9例，两组不良反应发生率比较差异有统计学意义（P<0.05）。治疗组复发率为3.4%，低于对照组的29.3%，差异有统计学意义（P<0.05）。结论：局部注射重组人干扰素α1b注射液治疗寻常疣疗效显著，复发率低，副作用少，值得临推广。 |
| 关键词: 重组人干扰素α1b注射液 CO2激光 寻常疣 儿童 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2016.11.008 |
|
| 基金项目: |
|
| Clinical Observation of Local Injection of Recombinant Human IFN-α1b in the Treatment of Verruca vulgaris |
| Li Can, Luo Xiaoyan, Wang Li; Ni Sili; Gan Liqiang |
| (Children's Hospital of Chongqing Medical University, Chongqing 400014, China) |
| Abstract: |
| Objective: To observe the efficacy and side effects of local injection of recombinant human interferon α1b (IFN-α1b) injection in the treatment of children verruca vulgaris. Methods: 116 cases of Verruca vulgaris were divided randomly into two groups, 58 cases in the treatment group and 58 cases in the control group. Conduct standard disinfection to treatment group, then extract appropriate amount of recombinant human IFN-α1b solution to inject verruca vulgaris at the base, until the verruca vulgaris local skin white, interval injection once a week and observe its effect. Use CO2 laser to treat control group, after using the same method of disinfection, directly burn the Verruca vulgaris through CO2 laser. Referral in a month, follow up after six months. Results: The local injection performs redness (3 cases), no blisters or infection in treatment group. While swelling (58 cases), vesicles (28 cases), or infection (9 cases) happens in control group. Compared to laser treatment, injection of IFN--α1b demonstrated similar efficacy, lower recurrence rate and fewer scars, pigmentation and other side effects. Conclusion: Local injection of recombinant human IFN-α1b have significant effect in the treatment of verruca vulgaris, low recurrence rate and few side effects, so it is worthy of clinical promotion. |
| Key words: recombinant human interferon α1b injection CO2 laser verruca vulgaris children |
